Advanced search
Publication Cover
Acta Oncologica Volume 29, 1990 - Issue 3
Journal homepage
1,128
Views
41
CrossRef citations to date
0
Altmetric
Original Article

Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

H. T. Mouridsen Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
C. Alfthan Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
L. Bastholt Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
J. Bergh Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
M. Dalmark Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
S. Eksborg Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
S. Hellsten Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
M. Kjaer Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
C. Peterson Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
T. Skovsgård Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
J. B. Sørensen Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
,
C. Tropé Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
&
K. Aabo Departments of Oncology, Odense University Hospital, Rigshospitalet, Copenhagen; Odense University Hospital, Odense; Aalborg City Hospital, Aalborg; University Hospital, Herlev; Department of Medicine F, Frederiksborg County Hospital, Hillerød, Denmark; Department of Urology, University Hospital, Helsinki, Finland; The Gynecologic Section, the Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, University of Uppsala, Uppsala; Department of Urology, General Hospital, Malmö; Department of Clinical Pharmacology, Karolinska Hospital, and Karolinska Pharmacy, Stockholm, Sweden
 show all
Pages 257-285 | Accepted 20 Jan 1990, Published online: 08 Jul 2009

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Kirsten Vang Nielsen, Bent Ejlertsen, Susanne Møller, Jan Trøst Jørgensen, Ann Knoop, Helle Knudsen & Henning T. Mouridsen. (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncologica 47:4, pages 725-734.
Read now
Helena Earl & Mahesh Iddawela. (2004) Epirubicin as adjuvant therapy in breast cancer. Expert Review of Anticancer Therapy 4:2, pages 189-195.
Read now
Jonas Bergh, Per-Ebbe Jönsson, Bengt Glimelius, Peter Nygren. (2001) A Systematic Overview of Chemotherapy Effects in Breast Cancer. Acta Oncologica 40:2-3, pages 253-281.
Read now
K. Sundby Hall. (1993) Contributions to the treatment of primary liver cancer. 4′-Epidoxorubicin and cisplatin studied in hepatocarcinoma cell cultures and in partially hepatectomized rats. Scandinavian Journal of Clinical and Laboratory Investigation 53:2, pages 101-109.
Read now
Per Pfeiffer, SØRen Cold & Carsten Rose. (1992) Cytotoxic Treatment of Metastatic Breast Cancer: Which drugs and drug combinations to use?. Acta Oncologica 31:2, pages 219-224.
Read now

Articles from other publishers (36)

Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler & Florian Fitzal. (2023) Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Ariunbuyan Sukhbaatar, Shiro Mori, Kiyoto Shiga & Tetsuya Kodama. (2023) Intralymphatic injection of chemotherapy drugs modulated with glucose improves their anticancer effect. Biomedicine & Pharmacotherapy 165, pages 115110.
Crossref
Radwan Ansaar, Robyn Meech & Andrew Rowland. (2023) A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution. Pharmaceutics 15:4, pages 1222.
Crossref
Alexey Surov, Maciej Pech, Daniel Gessner, Martin Mikusko, Thomas Fischer, Mareike Alter & Andreas Wienke. (2021) Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clinical Nutrition 40:10, pages 5298-5310.
Crossref
Sang Hyun Yoo, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Min Soo Choo & Ja Hyeon Ku. (2019) Intravesical Chemotherapy after Radical Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine 8:7, pages 1059.
Crossref
Adam J. Shuhendler, Preethy Prasad, Rui Xue Zhang, Mohammad Ali Amini, Mei Sun, Peter P. Liu, Robert G. Bristow, Andrew M. Rauth & Xiao Yu Wu. (2014) Synergistic Nanoparticulate Drug Combination Overcomes Multidrug Resistance, Increases Efficacy, and Reduces Cardiotoxicity in a Nonimmunocompromised Breast Tumor Model. Molecular Pharmaceutics 11:8, pages 2659-2674.
Crossref
Nadezhda Angelova & Georgi Yordanov. (2014) Nanoparticles of poly(styrene-co-maleic acid) as colloidal carriers for the anticancer drug epirubicin. Colloids and Surfaces A: Physicochemical and Engineering Aspects 452, pages 73-81.
Crossref
Zorka Bedzhova & Georgi Yordanov. (2013) Preparation of epirubicin-loaded poly(butyl cyanoacrylate) colloidal particles by polymerization in a mixed organic–aqueous solvent system. Colloids and Surfaces A: Physicochemical and Engineering Aspects 431, pages 27-33.
Crossref
David Cragg, Gordon Kingston & David NewmanFederico-Maria Arcamone. 2011. Anticancer Agents from Natural Products, Second Edition. Anticancer Agents from Natural Products, Second Edition 383 406 .
Ya-Chen Tina Shih, I-Wen Pan & Yi-Wen Tsai. (2009) Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries. PharmacoEconomics 27:11, pages 947-961.
Crossref
Derick Lau, Jewel Johl, Minh Huynh, Angela Davies, Michael Tanaka, Primo Lara & David Gandara. (2008) Population-Based Phase I Trial of Irinotecan and Epirubicin. American Journal of Clinical Oncology 31:3, pages 226-230.
Crossref
Bent Ejlertsen, Henning T. Mouridsen, Maj-Britt Jensen, J?rn Andersen, S?ren Cold, Per Edlund, Marianne Ewertz, Brita B. Jensen, Claus Kamby, Bo Nordenskjold & Jonas Bergh. (2007) Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. European Journal of Cancer 43:5, pages 877-884.
Crossref
Danyelle Townsend. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference 1 5 .
K. -H. Zurborn. 2006. Praktische Arzneitherapie. Praktische Arzneitherapie 561 638 .
Federico Maria Arcamone. 2005. Anticancer Agents from Natural Products. Anticancer Agents from Natural Products.
S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, N. Azarnia & L.W. Lee. (2004) Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of Oncology 15:10, pages 1527-1534.
Crossref
Fedro Peccatori, Giovanni Martinelli, Oreste Gentilini & Aron Goldhirsch. (2004) Chemotherapy during pregnancy: what is really safe?. The Lancet Oncology 5:7, pages 398.
Crossref
Bent Ejlertsen, Henning T. Mouridsen, Sven T. Langkjer, Jorn Andersen, Johanna Sjöström & Mogens Kjaer. (2004) Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403). Journal of Clinical Oncology 22:12, pages 2313-2320.
Crossref
Virginia G. Kaklamani & William J. Gradishar. (2003) Epirubicin Versus Doxorubicin: Which Is the Anthracycline of Choice for the Treatment of Breast Cancer?. Clinical Breast Cancer 4, pages S26-S33.
Crossref
K.-H. Zurborn. 2003. Praktische Arzneitherapie. Praktische Arzneitherapie 553 632 .
Manisha Bhutani, Lalit Kumar, Amish Vora, Narendra Bhardwaj, Ashutosh Kumar Pathak, Rajvir Singh & Vinod Kochupillai. (2002) Randomized study comparing 4′‐epi‐doxorubicin (Epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia. American Journal of Hematology 71:4, pages 241-247.
Crossref
G. Mustacchi, M. Muggia, S. Milani, R. Ceccherini, M.L. Leita & C. Dellach. (2002) A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Annals of Oncology 13:11, pages 1730-1736.
Crossref
F.C. Maluf & D. Spriggs. (2002) Anthracyclines in the Treatment of Gynecologic Malignancies. Gynecologic Oncology 85:1, pages 18-31.
Crossref
Giuseppe Sacco, Mario Bigioni, Stefano Evangelista, Cristina Goso, Stefano Manzini & Carlo A. Maggi. (2001) Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. European Journal of Pharmacology 414:1, pages 71-78.
Crossref
Tetsuro Kobayashi, Hiroki Koyama, Takahiro Oka, Tadaki Yasumura, Norimichi Kan, Yuichi Takatsuka, Masakuni Noguchi, Ken Morimoto, Takaichiro Suzuki, Takayoshi Tobe & Takesada Mori. (1999) Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer. Breast Cancer 6:1, pages 37-42.
Crossref
Ylva A. Karlsson, Per O. Malmstr�m, Thomas Hatschek, Tommy G. Fornander, Martin S�derberg, Nils-Olof Bengtsson, Tomas E. Jansson, Sara M. Sj�berg & Jonas C. Bergh. (1998) Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide. Cancer 83:5, pages 936-947.
Crossref
M. Michael, G. C. Toner, I. N. Olver, A. Fenessy & J. F. Bishop. (1997) Phase I Dose Intensification Study of 2-Weekly Epirubicin with GM-CSF in Advanced Cancer. American Journal of Clinical Oncology 20:3, pages 259-262.
Crossref
Elizabeth A. Lowenthal & John T. CarpenterJr.Jr.. (1995) The use of anthracyclines in the adjuvant treatment of breast cancer. Cancer Treatment Reviews 21:3, pages 199-214.
Crossref
M. Spielmann, D. Gandia, K. Fizazi, T. Guillot, E. Cvitkovic, L. Kayitalire, T. Girinsky, D. Elias, P. Rougier & J. Kac. (1994) Phase II study of 4?epirubicin in advanced squamous cell oesophageal cancer. European Journal of Cancer 30:12, pages 1908-1909.
Crossref
Sumitra Thongprasert & Kriangsak Jiamsriponges. (1993) Ifosfamide, epirubicin and cisplatin (IEP): another active combination for small cell lung cancer (SCLC). Lung Cancer 10:1-2, pages 91-94.
Crossref
A. Paul Launchbury & Nassir Habboubi. (1993) Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treatment Reviews 19:3, pages 197-228.
Crossref
G. Bonadonna, L. Gianni, A. Santoro, V. Bonfante, P. Bidoli, P. Casali, R. Demicheli & P. Valagussa. (1993) Drugs ten years later: Epirubicin. Annals of Oncology 4:5, pages 359-369.
Crossref
Jens Benn S�rensen, Lars Stenbygaard, Lars Drivsholm, Per Dombernowsky & Heine H. Hansen. (1993) Phase II study of 4?-iodo-4?-deoxydoxorubicin in non-resectable non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 32:5, pages 399-402.
Crossref
Staffan Eksborg, Lennart Hardell, Nils-Olof Bengtsson, Marie Sjödin & Birgitta Elfsson. (1992) Epirubicin as a single agent therapy for the treatment of breast cancer — A pharmacokinetic and clinical study. Medical Oncology and Tumor Pharmacotherapy 9:2, pages 75-80.
Crossref
Seppo O Pyrh?nen & Mauri O Kouri. (1992) Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. European Journal of Cancer 28:11, pages 1828-1832.
Crossref
Mikael J. Kajanti & Seppo O. Pyrh?nen. (1991) Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma. European Journal of Cancer and Clinical Oncology 27:12, pages 1620-1622.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.